DOI: 10.1186/s13550-018-0373-9Pages: 1-9

Biokinetic and dosimetric aspects of 64CuCl2 in human prostate cancer: possible theranostic implications

1. E.O. Galliera Hospital, Medical Physics Department

2. Galliera Hospital, Department of Nuclear Medicine

3. Galliera Hospital, Clinical Trial Unit, Office of the Scientific Director

4. E.O. Galliera Hospital, Department of Radiology

5. Oncology Institute of Southern Switzerland, Department of Nuclear Medicine

Correspondence to:
Arnoldo Piccardo
Tel: +39-0105634541
Email: arnoldo.piccardo@galliera.it

Close

Abstract

Background

The aim of the present study is to evaluate the kinetics and dosimetry of 64CuCl2 in human prostate cancer (PCa) lesions.

We prospectively evaluated 50 PCa patients with biochemical relapse after surgery or external beam radiation therapy. All patients underwent 64CuCl2-PET/CT to detect PCa recurrence/metastases. Volumes of interest were manually drawn for each 64CuCl2 avid PCa lesion with a diameter > 1 cm on mpMRI in each patient. Time-activity curves for all lesions were obtained. The effective and biological half-life and the standard uptake values (SUVs) were calculated. Tumour/background ratio (TBR) curves as a function of time were considered. Finally, the absorbed dose per lesion was estimated.

Results

The mean effective half-life of 64CuCl2 calculated in the lymph nodes (10.2 ± 1.7 h) was significantly higher than in local relapses (8.8 ± 1.1 h) and similar to that seen in bone metastases (9.0 ± 0.4 h). The mean 64CuCl2 SUVmax calculated 1 h after tracer injection was significantly higher in the lymph nodes (6.8 ± 4.3) and bone metastases (6.8 ± 2.9) than in local relapses (4.7 ± 2.4). TBR mean curve of 64CuCl2 revealed that the calculated TBRmax value was 5.0, 7.0, and 6.2 in local relapse and lymph node and bone metastases, respectively, and it was achieved about 1 h after 64CuCl2 injection. The mean absorbed dose of the PCa lesions per administrated activity was 6.00E-2 ± 4.74E-2mGy/MBq. Indeed, for an administered activity of 3.7 GBq, the mean dose absorbed by the lesion would be 0.22 Gy.

Conclusions

Dosimetry showed that the dose absorbed by PCa recurrences/metastases per administrated activity was low. The dosimetric study performed does not take into account the possible therapeutic effect of the Auger electrons. Clinical trials are needed to evaluate 64Cu internalization in the cell nucleus that seems related to the therapeutic effectiveness reported in preclinical studies.

This article is freely available, click here to access the full text/PDF

  • Accepted: Feb 20, 2018
  • Online: Mar 1, 2018

Article Tools

eanm
EJNMMI Ad